疑似颅内脑膜瘤患者生长抑素受体PET/CT与组织病理学相关性的回顾性评价
该回顾性研究分析了2006至2021年间223次因疑似脑膜瘤行SSTR PET/CT的检查,240个病灶与4个月内组织病理学结果匹配。SSTR PET/CT诊断脑膜瘤的灵敏度为100%(95%CI 98.4%-100%),特异度为61.1%(95%CI 35.8%-82.7%),阳性预测值96.9%(95%CI 93.8%-98.8%),阴性预测值100%(95%CI 71.5%-100%),总体诊断准确率97.1%。作者结论认为SSTR PET/CT是检测颅内脑膜瘤的精确影像方法,但2.9%的病例PET/CT阳性而组织病理学未确认脑膜瘤。
要点
- SSTR PET/CT检测脑膜瘤灵敏度100%(95%CI 98.4%-100%),特异度61.1%(95%CI 35.8%-82.7%)。
- 240个病灶中222个(92.5%)经SSTR PET/CT准确识别并由组织病理学确认。
- SUVmax预测组织病理学结果的ROC曲线下面积为94%。
核心结论
- SSTR PET/CT是检测颅内脑膜瘤的精确影像方法,表现为高灵敏度。
- 2.9%的病例尽管PET/CT阳性,组织病理学未确认脑膜瘤存在。
- 整合MRI、组织病理学和SSTR PET/CT有助于支持知情的治疗决策。
研究设计与样本
- 回顾性分析2006至2021年间本机构数据库记录的8077次SSTR影像检查。
- 其中223次SSTR PET/CT因疑似脑膜瘤而进行,240个病灶与4个月内组织病理学结果匹配。
- 回顾性审阅SSTR PET/CT报告与组织病理学结果以评估颅内脑膜瘤的存在,并计算诊断效能指标及每个病灶的SUVmax、SUVmean和SUVpeak。
主要发现
- 240个病灶中222个(92.5%)经SSTR PET/CT准确识别并由组织病理学确认脑膜瘤。
- 7例(2.9%)SSTR PET/CT疑似脑膜瘤但组织病理学未确认(假阳性)。
- 11例(5%)SSTR PET/CT未疑似脑膜瘤且组织病理学未确认(真阴性)。
- 本队列中无假阴性发现。
- SSTR PET/CT检测脑膜瘤的灵敏度为100%(95%CI 98.4%-100%),特异度为61.1%(95%CI 35.8%-82.7%),阳性预测值为96.9%(95%CI 93.8%-98.8%),阴性预测值为100%(95%CI 71.5%-100%),总体诊断准确率为97.1%。
关键数值与推荐
- 灵敏度100%(95%CI 98.4%-100%),特异度61.1%(95%CI 35.8%-82.7%)。
- 阳性预测值96.9%(95%CI 93.8%-98.8%),阴性预测值100%(95%CI 71.5%-100%)。
- 总体诊断准确率97.1%。
- SUVmax预测组织病理学结果的ROC曲线下面积为94%。
临床怎么用
- 作者结论认为SSTR PET/CT是检测颅内脑膜瘤的精确影像方法,表现为高灵敏度。
- 作者指出2.9%的病例尽管PET/CT阳性,组织病理学未确认脑膜瘤存在。
- 作者认为整合MRI、组织病理学和SSTR PET/CT有助于支持知情的治疗决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The aim of this retrospective study was to evaluate the correlation between findings from somatostatin receptor (SSTR) PET/CT and histopathology in patients with suspected intracranial meningiomas. Methods: We conducted a retrospective analysis of 8,077 SSTR imaging studies recorded in our institutional database between 2006 and 2021. In total, 223 SSTR PET/CT scans were performed for suspected meningioma, and 240 lesions were matched with histopathology results within 4 mo. Reports from SSTR PET/CT scans and histopathology were retrospectively reviewed to assess the presence of intracranial meningiomas. The positive and negative predictive values, sensitivity, specificity, and overall diagnostic accuracy of SSTR PET/CT were calculated. The SUVmax, SUVmean, and SUVpeak were determined for each lesion. Results: In 222 (92.5%) of 240 lesions, meningioma was accurately identified by SSTR PET/CT and confirmed by histopathology. In 7 cases (2.9%), SSTR PET/CT suspected meningioma was not confirmed by histopathology (false-positive). Furthermore, in 11 cases (5%), meningioma was neither suspected by SSTR PET/CT nor confirmed by histopathology (true-negative result). There were no false-negative findings in our cohort. SSTR PET/CT demonstrated a sensitivity of 100% (95% CI, 98.4%-100%) and a specificity of 61.1% (95% CI, 35.8%-82.7%) in detecting meningiomas. Positive predictive value was 96.9% (95% CI, 93.8%-98.8%), and negative predictive value was 100% (95% CI, 71.5%-100%). The overall diagnostic accuracy was 97.1%. The receiver-operating-characteristic analysis for SUVmax in predicting histopathology results showed an area under the curve of 94%, indicating an excellent ability of SUVmax to distinguish between positive and negative histopathologic findings. Conclusion: SSTR PET/CT is a precise imaging modality for detecting intracranial meningiomas, as demonstrated by its high sensitivity. However, in 2.9% of cases, despite a positive PET/CT result, histopathology did not confirm the presence of a meningioma. Integration of MRI, histopathology, and SSTR PET/CT supports informed treatment decisions.
引用
- Ebner R, Braach J, Rübenthaler J, et al. Retrospective Evaluation of the Correlation Between Somatostatin Receptor PET/CT and Histopathology in Patients with Suspected Intracranial Meningiomas. J Nucl Med. 2025. PMID: 40935608. doi:10.2967/jnumed.125.270115
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。